GeneDx and the End of the "Specialty Dx Can't Make Money" Joke
Los Angeles, March 15, 2025 — For years, one of the running jokes in diagnostics was that specialty Dx companies could do almost everything except make money. They could publish great science, build beautiful lab workflows, help patients, generate data assets, convince investors that the TAM was enormous. But profits? That was usually where the conversation got a little quieter.
To be clear, we are not talking about Quest or Labcorp. Those are scaled laboratory businesses that know how to make money. We are talking about specialty diagnostics companies running complex, high-value tests — oncology, rare disease, molecular profiling, MRD, genomics — where the science often looked better than the P&L.
For a long time, the industry's implicit bargain was: "Trust us, the clinical value is real, and the economics will eventually follow." Investors eventually asked a very rude question: "When?"
That is why GeneDx is such an important case study. The story is not simply that whole genome sequencing is cool. It is — I have known that for a while, as #NGSisUnstoppable. I digress — the story is that GeneDx appears to be moving from a structurally difficult specialty Dx model — lots of lower-ASP panels, reimbursement friction, and mixed profitability — toward a model where the test itself has enough clinical utility and reimbursement support to produce attractive unit economics.
That is a big deal! The core move is simple: replace a lower-value targeted panel business with higher-value whole exome and whole genome sequencing. In rough terms, this is the shift from a few-hundred-dollar NGS panel with modest gross margins to a multi-thousand-dollar exome/genome test with much stronger gross margins. Targeted panels at ~$400 blended ASP and ~30% historical gross margin, versus whole exome / whole genome at ~$3,000 blended ASP and ~80% historical gross margin. Management is also guiding whole exome / genome volume and revenue growth of ~40% in 2025.
That is escape velocity! It is the difference between selling a test that answers a narrow question and selling a diagnostic engine that can materially shorten the rare disease odyssey. And in pediatrics, neurology, developmental delay, epilepsy, autism, NICU settings, and other rare disease use cases, broader sequencing is not just "more data." It can be the difference between years of diagnostic wandering and a clearer path forward.
That clinical utility is what makes the economics believable. In diagnostics, reimbursement does not improve because a test is intellectually elegant. Payors are not known for rewarding elegance. If they were, every diagnostic report would come with a tip jar. Reimbursement improves when a test changes clinical decision-making, reduces downstream waste, improves yield, or addresses a meaningful unmet need.
GeneDx is starting to benefit from that dynamic. Whole exome and genome coverage is expanding among commercial payors and Medicaid programs. GeneDx is contracted with payors covering >80% of commercial lives, while 32 states cover exome or genome outpatient testing and 14 states cover rapid whole genome sequencing in the inpatient setting — both up meaningfully from 2021. There is still a lot of work to do, including reducing "no-pay" volume, but the reimbursement backdrop is clearly moving in the right direction.
This is where the specialty Dx narrative starts to change! For years, investors were asked to underwrite science first and economics later. Now, at least in parts of the market, we are seeing the two converge. GeneDx is showing that a test can be clinically better, reimbursed better, and margin better — which, in specialty diagnostics, is basically the triple crown. Or at least the first time someone has let diagnostics sit at the adult table without asking about cash burn.
The financial evidence is starting to show up. GeneDx's adjusted gross margin improved from 45% in 2023 to 65% in 2024, with management guiding up in 2025. The company also turned adjusted net income positive in 3Q24 and finished 2024 profitable on that basis. That is the part of the story that matters most: it is a margin architecture story.
And it has implications beyond GeneDx. If specialty Dx companies can move from under-reimbursed, semi-commoditized tests to high-utility, high-ASP, high-margin platforms, the sector starts to look very different. The old criticism was that complex diagnostics were "great for medicine, bad for shareholders." GeneDx is one of the clearest examples that this may no longer have to be true.
The bigger lesson is that complexity can be monetized when it is tied to clinical utility. A $400 panel with 30% gross margin is a hard business. A $3,000–$6,000 exome or genome test with strong gross margins, strong interpretation, and expanding coverage is a different animal. Same broad category — genetic testing — but very different economics. One is a lab service fighting gravity. The other can become a platform.
Of course, risks remain. Adoption is not automatic. Some clinicians are still comfortable with targeted panels. Payor-preferred vendor dynamics can shift. No-pay volumes still matter. NICU penetration will take work. And rare disease markets, while large in aggregate, are operationally fragmented. But the direction is important. GeneDx is proving that WGS has clinical utility, and that specialty diagnostics can finally translate clinical utility into financial utility.
For a sector that has spent years apologizing for its P&L, that is a meaningful turn. The punchline may be that specialty Dx was never inherently unprofitable. It was just often under-reimbursed, under-scaled, and stuck selling the wrong level of answer.
Maybe the new joke is that specialty Dx companies can make money after all. They just needed to stop selling $500 questions when medicine increasingly needs $6,000 answers.